Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 440
- Registration Number
- NCT04982237
- Locations
- 🇨🇳
Women's Hospital School Of Medicine Zhejiang University, Hangzhou, China
🇨🇳The Second Affiliated Hospital,Anhui Medical University, Hefei, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 172
- Registration Number
- NCT04974944
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT04973904
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Unresectable Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04971187
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Using ctDNA to Determine Therapies for Lung Cancer
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 66
- Registration Number
- NCT04966663
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 531
- Registration Number
- NCT04956692
- Locations
- 🇫🇷
Institut Regional du Cancer de Montpellier - ICM ( Site 1003), Montpellier, Herault, France
🇺🇸St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, United States
🇺🇸West Virginia University ( Site 0056), Morgantown, West Virginia, United States
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 550
- Registration Number
- NCT04956640
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, Rhône-Alpes, France
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇦🇺Peninsula and Southeast Oncology, Frankston, Victoria, Australia
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- CanBas Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04953962
- Locations
- 🇺🇸
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Texas Oncology- McKinney, McKinney, Texas, United States
🇺🇸Ochsner Clinic Foundation, Los Angeles, California, United States
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT04951115
- Locations
- 🇺🇸
New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸New York-Presbyterian Queens, Flushing, New York, United States
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 862
- Registration Number
- NCT04949256
- Locations
- 🇨🇷
PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica
🇨🇳Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China
🇨🇳West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.